Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03326310
Title Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.